Lowering Blood Pressure in Primary Care in Vienna

• Status: Completed
• Trial end date: 2017-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (SPC), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wilhelminenspital Vienna
• Collaborators: Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology; Ludwig Boltzmann Foundation for Cardiovascular Research
• Treatments: Amlodipine; Angiotensin Receptor Antagonists; Calcium Channel Blockers; Hydrochlorothiazide; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Written informed consent

• office blood pressure ≥ 140/90 mmHg

• ACE inhibitor intolerance (experimental arm)

Exclusion Criteria:

• Malignant disease with life expectancy < 6 months

• Women of childbearing potential (ICH definition) or breastfeeding

• Contraindications or allergies against olmesartan, amlodipine or hydrochlorothiazide (experimental arm)

• Chronic kidney disease grade IV or V (eGFR < 30 ml/min)

• Recent myocardial infarction or stroke within the preceding 3 months

• Participation in another clinical trial